Guardant Health, Inc. has announced significant findings from the Phase III SERENA-6 trial, demonstrating the clinical effectiveness of the Guardant360® CDx test in guiding treatment for breast cancer. The study showed that using a circulating tumor DNA-guided approach, the Guardant360 CDx test can detect emerging resistance in 1st-line therapy before radiological disease progression in advanced breast cancer. Results indicated that AstraZeneca's camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer who had an emergent ESR1 tumor mutation. These findings, presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, highlight a new paradigm in using liquid biopsy to inform timely treatment changes, potentially improving patient outcomes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。